Le Lézard
Classified in: Science and technology, Covid-19 virus
Subjects: Contract/Agreement, Product/Service, Sales, Funding

Capitolis Novations Posts Record Transaction Volumes in Q1 2021, Adds New Clients and Functionalities to Platform


Capitolis, the leading provider of SaaS and structured financing products that address balance sheet management for financial institutions, today announced that Novations, its foreign exchange novation platform, achieved a record transaction volume of more than $959 billion in notional for FX options novations during the first quarter ended April 30, 2021, more than doubling the volume from a year earlier.

Many financial institutions expanded their positions in the FX market during the periods of volatility brought on by the COVID-19 pandemic, and they turned to the Capitolis platform to open them up to further opportunities in the market without adding risk. Trading volumes continue to hold at record highs, making the demand for Capitolis' analytics and tools stronger than ever across both buy side and sell side institutions.

"The Capitolis platform is a truly groundbreaking technology that enables the world's leading prime brokers, executing banks, hedge funds, and money managers to more effectively interact and manage their balance sheets, unlocking the potential to completely transform how firms trade with one another," said Ben Tobin, Senior Vice President, Global Head of FX at Capitolis. "The growth of Novations over the past year has been tremendous, and we look forward to continually expanding to support our existing and prospective clients with solutions that meet their complex balance sheet needs."

In addition to achieving record volumes, Capitolis has added 11 clients to the Novations platform since August. These new clients, across both the buy and sell side, complement a growing roster of more than 75 leading global financial institutions currently active on the Novations platform, including NatWest, Citi, HSBC, Standard Chartered, Nomura, and Societe Generale. Since its inception nearly three years ago, Capitolis Novations has eliminated positions of more than $4.6 trillion in notional.

To support the growth of Novations, Capitolis has added key features for an improved user experience, including enhanced functionalities that simplify the movement of FX instruments between prime brokers and the larger marketplace, and advanced analytics on the status of all pending and completed novations.

The growth of Capitolis' Novations platform follows the recent completion of a $90 million Series C funding round led by Andreessen Horowitz. Capitolis further bolstered its positioning in the FX space earlier this year, announcing a partnership with leading FX settlement provider CLS to streamline trading and settlement for banks in the $6.6 trillion global currency market.

For more information about Capitolis, please visit www.capitolis.com.

ABOUT CAPITOLIS

Capitolis is the leading SaaS platform that drives financial resource optimization for capital markets. Founded in 2017, our network software enables financial institutions to optimize their balance sheets, which creates a fairer, safer, and healthier marketplace. More than 75 financial institutions, including banks, hedge funds, and asset managers, leverage Capitolis technology to bring the best services to market and achieve high levels of return, while using the most appropriate amounts of their financial resources.

Capitolis is backed by world class venture capital firms, including Andreessen Horowitz, Index Ventures, Sequoia Capital, Spark Capital, SVB Capital, and S Capital, as well as leading global banks such as Citi, J.P. Morgan, and State Street. Our team brings decades of experience in launching successful startups, technology, and financial services and is growing rapidly in our offices in New York, London, and Tel Aviv. For more information, please visit our website at www.capitolis.com or follow us on LinkedIn.


These press releases may also interest you

at 01:20
Biophytis SA (Euronext Growth Paris:ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company specialized in thedevelopment oftherapeutics for age-related diseases, today annouces that it will change the ratio...

18 avr 2024
The report titled "Clinical Trials Matching Software Market by Functionality (Analytics & Reporting, Compliance Tracking, Data Management), Deployment (Cloud & Web Based, On-Premise), End-Use - Global Forecast 2024-2030" is now available on...

18 avr 2024
South Korea's biotechnology company Hyundai Bioscience (CEO Oh Sang-gi, www.hyundaibioscience.com) announced on April 15 that it would carry out global clinical tests aimed at treating all serotypes of Dengue virus infection....

18 avr 2024
The economic turmoil triggered by the COVID-19 pandemic has led to a sharp decrease in the number of self-employed individuals in the United States, with a 22% reduction...

18 avr 2024
WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of common stock of QuidelOrtho Corporation between February 18, 2022 and April 1, 2024, both dates inclusive (the "Class...

18 avr 2024
Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved ENTYVIO® (vedolizumab) subcutaneous (SC) administration for maintenance therapy in adults with moderately to severely active Crohn's disease (CD)...



News published on and distributed by: